BRADBURY DANIEL 4

What Happened

• Daniel Bradbury, a director of Castle Biosciences (CSTL), reported the conversion/exercise of 13,667 restricted stock units (RSUs) into 13,667 shares on May 22, 2026. The reported consideration for the transfer was $0.00, indicating the RSUs settled into shares without cash payment and the shares were moved into the Bradbury Family Trust.

Key Details

• Transaction date: 2026-05-22; Form 4 filed: 2026-05-27 (filed within the SEC’s 2-business-day window).
• Transaction code: M (exercise or conversion of a derivative/RSU).
• Shares involved: 13,667 shares acquired via conversion and 13,667 shares reported as disposed at $0.00 (settlement/transfer).
• Shares owned after transaction: Not specified in the excerpt provided.
• Footnotes of note:
  • F1: Each RSU equals the right to one share of common stock.
  • F2: Shares are held by the Bradbury Family Trust (the reporting person and Annette Bradbury are trustees/beneficiaries).
  • F3: The RSUs vest in full on the earlier of one year after May 22, 2026, or the day before the next annual meeting of stockholders.

Context

• This filing documents settlement/conversion of RSUs (an award settlement), not an open-market purchase or sale. The $0.00 disposition indicates a transfer into a family trust rather than a sale for cash. Such conversions are typically part of compensation or estate-planning transactions and do not, by themselves, indicate a change in the insider’s market view.